Tezepelumab decreases matrix remodelling and inflammatory pathways in patients with asthma
| Autor: | Wendy I. White, Yuling Wu, Jane R. Parnes, Jennifer Kearley, Wei Zhao, Sriram Sridhar, Janet Griffiths, Tuyet-Hang Pham, Lorin Roskos |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Thymic stromal lymphopoietin
biology business.industry Interleukin 5 receptor alpha subunit Inflammation Periostin medicine.disease Placebo Immunoglobulin E Blood proteins 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Immunology biology.protein Medicine 030212 general & internal medicine medicine.symptom business Asthma |
| Zdroj: | Airway pharmacology and treatment. |
| DOI: | 10.1183/13993003.congress-2019.rct3785 |
| Popis: | Background: Tezepelumab, a human monoclonal antibody that selectively blocks thymic stromal lymphopoietin interaction (TSLP) with its receptor, improved clinical outcomes vs. placebo in patients with severe, uncontrolled asthma (Phase 2b PATHWAY study [NCT02054130]). Proteomics analysis was performed to further elucidate mechanisms of tezepelumab activity in patients with asthma. Aim: To determine which serum proteins are altered by tezepelumab. Methods: Patients were randomised to tezepelumab-treatment arms or placebo (Corren et al. NEJM 2017;377:936–46). Serum protein levels were assessed at baseline and at multiple post-treatment timepoints up to Week 52 using the Myriad Rules Based Medicine (RBM) and SomaLogic platforms (122 and 1305 analytes, respectively). Significant changes were determined by ANOVA and t-tests at each timepoint, with percent changes from baseline also being assessed. We also explored associations between baseline levels of RBM proteins and clinical biomarkers. Results: Levels of matrix remodelling (MMP-10, periostin), eosinophil-related (IL5RA, PAPP‑A), IgE and TARC proteins decreased significantly post-treatment (>10% change in tezepelumab vs. placebo at Week 52, p Conclusions: Tezepelumab led to a decrease in biomarkers of inflammation and matrix remodelling, which were correlated with bEOS and FENO levels at baseline. Modulation of matrix remodelling proteins may reflect a novel mechanism of action for tezepelumab in addition to the inhibition of airway inflammation. Co-sponsored by MedImmune, a member of the AstraZeneca Group, and Amgen Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|